OrthoPediatrics (NASDAQ:KIDS) Director David Pelizzon Sells 10,131 Shares of Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 10,131 shares of the company’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $23.10, for a total value of $234,026.10. Following the sale, the director owned 6,526,633 shares of the company’s stock, valued at $150,765,222.30. This represents a 0.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

OrthoPediatrics Trading Down 1.3%

Shares of OrthoPediatrics stock traded down $0.31 during trading hours on Tuesday, reaching $23.00. The stock had a trading volume of 139,797 shares, compared to its average volume of 173,766. The firm has a market capitalization of $600.53 million, a price-to-earnings ratio of -13.69 and a beta of 0.98. OrthoPediatrics Corp. has a 1 year low of $14.42 and a 1 year high of $26.74. The company has a current ratio of 4.78, a quick ratio of 2.17 and a debt-to-equity ratio of 0.28. The firm has a 50 day simple moving average of $21.52 and a two-hundred day simple moving average of $18.72.

OrthoPediatrics (NASDAQ:KIDS) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The business had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. As a group, equities research analysts anticipate that OrthoPediatrics Corp. will post -1.14 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on KIDS. Truist Financial set a $22.00 target price on shares of OrthoPediatrics in a research note on Wednesday, August 5th. TD Cowen reaffirmed a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. BTIG Research increased their price target on OrthoPediatrics from $24.00 to $29.00 and gave the company a “buy” rating in a report on Thursday, August 20th. Needham & Company LLC raised their price objective on OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, OrthoPediatrics currently has an average rating of “Moderate Buy” and a consensus price target of $26.44.

Hedge Funds Weigh In On OrthoPediatrics

A number of institutional investors and hedge funds have recently bought and sold shares of KIDS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in OrthoPediatrics by 6.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after acquiring an additional 645 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of OrthoPediatrics by 433.1% during the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after purchasing an additional 1,139 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of OrthoPediatrics by 60.2% during the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after purchasing an additional 1,235 shares in the last quarter. Legal & General Group Plc purchased a new position in shares of OrthoPediatrics in the second quarter valued at $34,000. Finally, Northwestern Mutual Wealth Management Co. boosted its stake in shares of OrthoPediatrics by 5,226.5% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after purchasing an additional 2,561 shares during the period. Hedge funds and other institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.